THK (6481) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
18 Mar, 2026Executive summary
Consolidated revenue for FY 2024 rose 0.2% year-on-year to ¥352.7 billion, with operating income down 26.8% to ¥17.3 billion due to lower volumes, higher fixed costs, and increased investments.
Revenue and operating income exceeded the revised plan announced in November 2024 by ¥2.7 billion and ¥0.3 billion, respectively.
Profit attributable to owners dropped 43.3% year-over-year to ¥10.4 billion.
New management policy targets early realization of ROE over 10%, focusing on profitability, capital efficiency, and structural reforms.
Comprehensive income remained stable at ¥35,212 million, supported by significant foreign exchange gains.
Financial highlights
Net sales decreased in Japan and Europe but increased in the Americas, China, and Asia, aided by a weaker yen.
Gross margin was 23.2%, unchanged from the previous year; operating margin declined to 4.9% from 6.7%.
Total assets reached ¥567.4 billion, up ¥11.1 billion year-on-year.
Cash and cash equivalents at year-end were ¥138,293 million, down from ¥156,486 million; inventories rose to 3.1 months of sales.
Profit attributable to owners was ¥10.4 billion, down 43.3% year-over-year.
Outlook and guidance
FY2025 forecast: revenue of ¥363.5 billion (+3.0% YoY), operating income of ¥23.5 billion (+35.5% YoY), and profit attributable to owners of ¥18.0 billion (+72.4% YoY).
Two-year period up to FY2026 defined as a structural reform phase, aiming for ROE over 10% between FY2027 and 2029.
Interim FY2025 guidance: revenue ¥173.3 billion, profit attributable to owners ¥5.0 billion.
Dividend policy targets DOE of 8%; FY2024 year-end dividend was ¥128.5 per share, total ¥146.5 per share.
Latest events from THK
- Major loss from business transfer drives net loss, but strong FY2026 recovery forecast.6481
Q4 202518 Mar 2026 - Revenue and profit declined, but China and Asia showed growth as equity fell on buybacks.6481
Q2 202518 Mar 2026 - Revenue and profit fell year-over-year, but recovery and new product initiatives support outlook.6481
Q2 202418 Mar 2026 - Profit plunged despite stable revenue, but full-year outlook and dividend were raised.6481
Q1 202518 Mar 2026 - Profit and revenue fell year-over-year, with margin pressure and cautious full-year outlook.6481
Q3 202418 Mar 2026 - Revenue up, but profits down sharply on higher costs and equity-method losses.6481
Q3 202511 Nov 2025